Stockscreener 앱 받기
2.94
1.38%
0.04
시간 외 거래:
2.99
0.05
+1.70%
전일 마감가:
$2.90
열려 있는:
$2.89
하루 거래량:
99,039
Relative Volume:
0.14
시가총액:
$432.74M
수익:
-
순이익/손실:
-
주가수익비율:
-13.08
EPS:
-0.2247
순현금흐름:
-
1주 성능:
+0.34%
1개월 성능:
+63.33%
6개월 성능:
+70.93%
1년 성능:
+37.38%
1일 변동 폭
$2.82
$2.975
1주일 범위
$2.80
$2.9985
52주 변동 폭
$1.32
$3.5299
Immutep Limited Adr Stock (IMMP) Company Profile
IMMP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
2.94 | 426.86M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-17 | 개시 | CapitalOne | Overweight |
| 2023-08-03 | 개시 | Robert W. Baird | Outperform |
| 2021-08-03 | 개시 | Ladenburg Thalmann | Buy |
| 2021-07-16 | 재개 | Maxim Group | Buy |
| 2018-09-28 | 개시 | B. Riley FBR | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
모두보기
Immutep Limited Adr 주식(IMMP)의 최신 뉴스
Why Immutep Limited (Common Stock) (YP1A) stock is trending on social mediaHealthcare Stock Analysis & Investment Portfolio Recommendations - Bollywood Helpline
Immutep (IMMP) reports positive IMP761 Phase I study update - Stock Titan
Why Wall Street Is Watching Immutep's Experimental Autoimmune Treatment Closely - Sahm
Will Immutep Limited Depositary Receipt stock see insider buying2025 Bull vs Bear & Accurate Intraday Trading Signals - Улправда
Why Immutep Limited (YP1B) stock is a strong analyst pickWeekly Risk Summary & AI Powered Trade Plan Recommendations - Улправда
[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC FilingForm 6-K - Stock Titan
Immutep Limited (IMMP): Firm Reports Positive Data from Trials - Finviz
Ready to Jump After Recent Trade: Beta Bionics Inc (BBNX) - setenews.com
An analyst sees good growth prospects for Immutep Limited ADR (IMMP) - setenews.com
Immutep Limited Announces 2025 AGM with Key Resolutions - MSN
IMMP 20-F highlights: pipeline progress, IFRS results, Nasdaq ADSs - Stock Titan
Immutep reports Phase II neoadjuvant efti success in sarcoma via 6-K - Stock Titan
Immutep Completes FDA Project Optimus, Advances Cancer Immunotherapy - MSN
Immutep files 6-K with exhibit on FDA Project Optimus completion - Stock Titan
Immutep Announces Successful Completion of FDA Project Optimus Requirements - The Manila Times
Is Immutep Limited Depositary Receipt stock ready for a breakoutPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Reversal indicators forming on Immutep Limited Depositary Receipt stockMarket Activity Summary & Safe Entry Point Alerts - newser.com
What momentum shifts mean for Immutep Limited Depositary Receipt2025 Bull vs Bear & AI Forecasted Stock Moves - newser.com
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 - GlobeNewswire Inc.
Immutep Limited Depositary Receipt Stock Lags Behind Sector BenchmarksMarket Performance Report & Weekly Setup with High ROI Potential - beatles.ru
Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa - Yahoo Finance
12 Best Australian Stocks to Buy Right Now - Insider Monkey
Immutep Gains FDA Support for Cancer Therapy Development - TipRanks
Is Immutep Limited Depositary Receipt a good long term investmentFree Stock Market Return Analysis - PrintWeekIndia
Immutep Limited Depositary Receipt Stock Analysis and ForecastExceptional gains - jammulinksnews.com
Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data - Finviz
Immutep Ltd Highlights Immune System Innovations at Healthcare Conference - TipRanks
Immutep stock soars on promising trial results By Investing.com - Investing.com Australia
Immutep stock soars on promising trial results - Investing.com
Immutep Advances Cancer Trials with Promising Developments - TipRanks
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now? - AInvest
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewswire
Immutep Limited (NASDAQ: IMMP)Share Price - intelligentinvestor.com.au
Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com
Immutep appoints research institute to conduct first-in-human study of IMP761 - Biotech Dispatch
symbol__ Stock Quote Price and Forecast - CNN
Immutep Announces Successful Meeting with the FDA on - GlobeNewswire
Immutep Announces GMP Manufacturing Process Developed for - GlobeNewswire
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - targetedonc.com
72 Biggest Movers From Friday - Benzinga
Immutep Limited (ASX: IMM) - The Motley Fool Australia
Immutep Limited Share Price ADR each Representing 10 Shares - Hargreaves Lansdown
Immutep valuation increased 16% to $510 million by Edison Investment Research - Proactive financial news
Technical Analysis of Immutep Ltd Sponsored ADR (NASDAQ:IMMP) - TradingView
IMM Stock Price and Chart — ASX:IMM - TradingView — Track All Markets
IMMP - Finviz
IMMP Stock Price | Immutep Ltd. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
Prima BioMed (IMMP) Stock Price, News & Analysis - MarketBeat
IMMP Stock Price and Chart — NASDAQ:IMMP - TradingView — Track All Markets
Zai Lab Limited (ZLAB) stock price, news, quote and history - Yahoo Finance UK
Immutep Limited Adr (IMMP) 재무 분석
Immutep Limited Adr (IMMP)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):